



April 13, 2006

Edward Hammond
The Sunshine Project
101 West 6th Street Suite 607
Austin TX, 78701

Dear Mr. Hamond:


This is in response to your email dated March 13, 2006.

In the future please send correspondence to Robert Lanford. I am the Chair of the Recombinant DNA Committee at SFBR. Jack Kelley the person you addressed the letter to is no longer at SFBR. He was the Health and Safety Officer.

We have previously provided The Sunshine Project with the meetings of our Recombinant DNA Committee. In response to your letter of June 9, 2004, we provided all minutes from January 1, 2000 to July 8, 2004. Enclosed we have provided an update of any new minutes from the Committee from our previous correspondence. We have also enclosed an updated roster of our Recombinant DNA Committee Membership. You will note that we have very few minutes, because we are a small institute that is not heavily invested into recombinant DNA research. Each month, if there are no applications, the meeting is canceled.

According to the OBA, we are under no obligation to provide The Sunshine Project with any information with regard to how our institute has responded to the report on Biotechnology Research in an Age of Terrorism and the 7 categories of experiments of concern.

Sincerely,



Robert E. Lanford, Ph.D.
Chair, Recombinant DNA Committee

Enclosures

TITLE/ACTION**APPROVED DATE**

Molecular Biology of Hepatitis B Virus Replication
Approved with revisions

April 7, 2005

GBV-B A Small Primate Model for HCV
Approved without discussion/comment

March 24, 2005

Analysis of Woolly Monkey Hepatitis Virus
Approved without discussion/comment

March 24, 2005

Analysis of Infectious Clones of Hepatitis C Virus
Approved without discussion/comment

March 24, 2005

RECOMBINANT DNA COMMITTEE

Dr. Robert Lanford, Chair

Dr. Rampratap Kushwaha

Dr. Tim Anderson

Dr. Krishna Murthy

Ms. Melina Kinsey, Safety Officer

Ms. Cynthia Calderon

Dr. Ellen B Kraig, external reviewer

Dr. David J. Kolodrubetz, external reviewer



Southwest Regional Primate Research Center and Southwest Foundation for Biomedical Research



Department of Virology and Immunology
Robert E. Lanford, Ph.D.
Scientist

June 4, 2004

Edward Hammond
The Sunshine Project
101 West 6th Street Suite 607
Austin TX, 78701

This is in response to your letter dated May 28, 2004. We acknowledge receipt of your request for minutes of our IBC meetings from June 1, 2003 to May 28, 2004. Please send all requests by registered mail, as we have no way of verifying the authenticity of a Fax that comes to a common Fax machine within our institute.

We have reviewed the requested records. No new proposals were submitted during the time frame of your request. We are a small institute that is not heavily invested in recombinant DNA research and some years pass without new proposals.

Sincerely,

A handwritten signature in blue ink, appearing to read "Robert E. Lanford".

Robert E. Lanford, Ph.D.
Chair, Recombinant DNA Committee



Southwest Regional Primate Research Center and Southwest Foundation for Biomedical Research



Department of Virology and Immunology

Robert E. Lanford, Ph.D.
Scientist

July 8, 2004

Edward Hammond
The Sunshine Project
101 West 6th Street Suite 607
Austin TX, 78701

This is in response to your email dated June 9, 2004.

I would like to clarify several issues. You suggested that we had not replied to your faxes, but in fact, our letter dated June 4, 2004 was in response to your fax. In that letter, we informed you that there were no applications to the Recombinant DNA Committee during the time frame you requested (June 2003 to present). We tried to explain to you that we are a small facility not heavily involved in recombinant DNA and that there were no applications during that period. We fail to recognize how this is in non-compliance with NIH guidelines.

Your more recent request is for minutes of the meetings from January 1, 2000 to present. Attached please find a list of the proposals during that time frame, minutes of any deliberations, and the relevant dates.

A copy of the roster that we submit to NIH is attached.

We had no other communications with NIH OBA during the time frame requested.

Finally, we did not require that you send correspondence by certified mail. We responded to your fax. We suggested that certified mail might be a more appropriate method of communication, since it provides some assurance that we receive your communications. You were sending faxes to a fax machine located in a common space for an entire department. This machine receives considerable spam, and we have no method of assuring that your communications will not be discarded by accident.

Sincerely,

A handwritten signature in blue ink, appearing to read "Robert E. Lanford".

Robert E. Lanford, Ph.D.
Chair, Recombinant DNA Committee



February 2, 2004

Eugene Rosenthal, Ph.D.
Biotechnology Program Advisor
Office of Biotechnology Activities
National Institutes of Health, MSC 7010
6000 Executive Blvd., Suite 302
Bethesda, Maryland 20892-7010

Dear Dr. Rosenthal:

In compliance with Section IV-B 2-a-(1) of the *NIH Guidelines for Research Involving Recombinant DNA Molecules, (NIH Guidelines)*, below is this institution's current IBC roster. There have been no changes in membership during the current year.

Dr. Robert E. Lanford, Chair
Dr. Timothy Anderson
Dr. Rampratap Kushwaha
Dr. Ellen B. Kraig
Dr. David J. Kolodrubetz

Sincerely,

Robert E. Lanford, Ph.D.
Scientist

REL/cc

TITLE/ACTION	APPROVED DATE
Molecular signature characterization and Protocol Development: Viral RG2 Approved without discussion/comment	January 20, 2000
Molecular signature characterization and Protocol Development: Viral RG3 Approved without discussion/comment	January 20, 2000
Macrophage targeting of mice exposed to instilled anthrax Approved without discussion/comment; one member deferred his review to the other members	April 17, 2000
New World Arenavirus Vaccines Discussion items: 1) creating the defective virus particles 2) Arenavirus antibody	April 17, 2000
Evaluate the performance of the cynomolgus EPO/GeneSwitch system in cynomolgus monkeys Administratively approved, BSL-1 vector involved	June 27, 2000
Determination of Prophylactic Efficacy of Various Hepatitis C Virus Vaccines in the Chimpanzees Discussion items: 1) Description of recombinant DNA to be used 2) Strain of HCV heterologous 1a 3) level of containment	September 17, 2001
Yellow Fever/West Nile chimera vaccine efficacy Discussion items: 1) Nature of construct 2) Chimera proposed as human vaccine 3) Percentage of virus that is West Nile vs Yellow Fever 4) Biohazard approval	November 1, 2001
Evaluation of experimental HIV vaccines in rhesus macaques Discussion items: 1) Plasmids are BSL1, less than 2/3 genome 2) Disposition of animals	February 25, 2002
Primate retroviral pathogenesis Administratively approved, extension of existing project	May 29, 2002
Yellow Fever/Arenavirus Recombinant Vaccine Discussion items: 1) ABSL room 2) Personnel safety	July 31, 2002
Develop a xenograft model to test anti-HIV-1 activity of rhesus macaque hematopoietic progenitor cells transduced with an intracellular anti-HIV-1 gp41 antibody gene in vivo Discussion items: 1) Precautions with T cells 2) Possibility of recombination of HIV and recombinant lentivirus. 2) Appropriate BSL2 facility	October 9, 2002
Viral Encapsulation and Nucleocapsid Interactions of Bunyaviridae Discussion items: 1) Expression system	November 5, 2002